Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Apyx Medical (APYX) over the last 16 years, with Q3 2025 value amounting to $1.8 million.

  • Apyx Medical's Other Non-Current Assets rose 151.26% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 151.26%. This contributed to the annual value of $1.7 million for FY2024, which is 392.61% down from last year.
  • Latest data reveals that Apyx Medical reported Other Non-Current Assets of $1.8 million as of Q3 2025, which was up 151.26% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Apyx Medical's Other Non-Current Assets registered a high of $1.9 million during Q2 2023, and its lowest value of $860000.0 during Q1 2021.
  • Its 5-year average for Other Non-Current Assets is $1.5 million, with a median of $1.7 million in 2024.
  • As far as peak fluctuations go, Apyx Medical's Other Non-Current Assets surged by 10767.72% in 2021, and later crashed by 639.2% in 2025.
  • Apyx Medical's Other Non-Current Assets (Quarter) stood at $1.1 million in 2021, then grew by 9.64% to $1.2 million in 2022, then soared by 42.32% to $1.7 million in 2023, then fell by 3.93% to $1.7 million in 2024, then grew by 8.89% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $1.7 million for Q2 2025, and $1.8 million during Q1 2025.